DeuteRx has pioneered ‘deuterium-enabled chiral switching’ (DECS), a revolutionary approach to improve racemic (a 1:1 mixture of two mirror-image compounds or stereoisomers) small molecule marketed drugs and drug candidates intended for patients across multiple therapeutic indications.
The development of the single, preferred stereoisomer from the parent racemic drug, also known as a ‘chiral switch’, often leads to drugs with superior therapeutic properties. However, numerous drugs are still developed and marketed as racemic mixtures because their stereoisomers chemically interconvert in vivo. Representative drugs include Actos® (pioglitazone), Aricept® (donepezil), Wellbutrin® (bupropion), and Revlimid® (lenalidomide). Replacing the exchangeable hydrogen at the chiral center with deuterium enables stabilization and characterization of the single, preferred stereoisomer with new composition of matter patent protection and an expedited path to market. To date, DeuteRx has demonstrated the use of DECS to stabilize and characterize the stereoisomers of many racemic active ingredients.
with New IP &